DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline

(2015) V. A. Gault et al.   DIABETES OBESITY & METABOLISM

Sitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reaction

(2015) Tzu-Hsien Tsai et al.   JOURNAL OF HYPERTENSION

Blood pressure variability, impaired autonomic function and vascular senescence in aged spontaneously hypertensive rats are ameliorated by angiotensin blockade

(2014) Daisuke Sueta et al.   ATHEROSCLEROSIS

DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure

(2014) Nobutaka Koibuchi et al.   Cardiovascular Diabetology

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

(2014) Bowen Lin et al.   Cardiovascular Diabetology

Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy

(2014) Yuliya Sharkovska et al.   JOURNAL OF HYPERTENSION

Rosuvastatin Ameliorates Early Brain Injury after Subarachnoid Hemorrhage via Suppression of Superoxide Formation and Nuclear Factor-Kappa B Activation in Rats

(2014) Ken Uekawa et al.   Journal of Stroke & Cerebrovascular Diseases

DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat

(2014) Ravi Nistala et al.   Obesity

Apoptosis Signal–Regulating Kinase 1 Is a Novel Target Molecule for Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion

(2013) Kensuke Toyama et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice

(2013) Dong Yang et al.   BRAIN RESEARCH

Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats

(2013) Annayya R. Aroor et al.   ENDOCRINOLOGY

DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats

(2013) Hiranya Pintana et al.   JOURNAL OF ENDOCRINOLOGY

Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease

(2013) Jayasankar Kosaraju et al.   NEUROPHARMACOLOGY

Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions

(2013) Geert Jan Biessels et al.   Lancet Diabetes & Endocrinology

Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus

(2012) Harshal R. Patil et al.   AMERICAN JOURNAL OF CARDIOLOGY

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease

(2012) Jixin Zhong et al.   ATHEROSCLEROSIS

Recent advances in incretin-based therapies

(2012) David Russell-Jones et al.   CLINICAL ENDOCRINOLOGY

Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease

(2012) Usha Panchapakesan et al.   CLINICAL SCIENCE

Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice

(2012) L. Chen et al.   CURRENT MOLECULAR MEDICINE

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride

(2012) V. Darsalia et al.   DIABETES

Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury

(2012) Matthew Campbell et al.   Nature Communications

Systemic low-molecular weight drug delivery to pre-selected neuronal regions

(2011) Matthew Campbell et al.   EMBO Molecular Medicine

Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease

(2011) Yi-Fei Dong et al.   FASEB JOURNAL

Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice

(2010) Masaya Fukuda et al.   JOURNAL OF HYPERTENSION

Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice

(2010) Yi-Fei Dong et al.   JOURNAL OF HYPERTENSION

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study

(2010) E. M. C. Schrijvers et al.   NEUROLOGY

Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama Study

(2010) T. Matsuzaki et al.   NEUROLOGY

Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes

(2009) Y. F. Dong et al.   DIABETOLOGIA

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice

(2009) Michele D’Amico et al.   EXPERIMENTAL GERONTOLOGY

Blood-brain barrier alterations in ageing and dementia

(2009) Bogdan O. Popescu et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Do in vivo Experimental Models Reflect Human Cerebral Small Vessel Disease? a Systematic Review

(2008) Atticus H Hainsworth et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM